Cadonilimab plus chemotherapy for advanced or recurrent endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial studies a new drug called cadonilimab combined with chemotherapy for women with endometrial cancer that has come back or spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage III, IVA, or recurrent endometrial cancer that cannot be treated with surgery or radiation.
- You have not had chemotherapy for advanced or recurrent disease, but prior adjuvant therapy (like chemo, radiation, or hormone therapy) is allowed if it ended at least 6 months ago for chemo, or 3 weeks for radiation or hormone therapy.
- You have a tumor sample (from a biopsy or surgery) that can be tested.
- You are generally well enough to care for yourself (ECOG score 0 or 1).
- Your blood counts and organ function are adequate, and you have not had certain other cancers or serious health conditions recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
This trial tests a combined treatment of the immunotherapy drug cadonilimab plus radiation and chemotherapy for endometrial cancer that has come back or spread to only a few places. The goal is to see if this combination can help control the cancer better.
This trial tests a drug called cadonilimab in women with cervical cancer that has returned or spread. The goal is to see how well it works in real life and to help manage the cancer.
This trial tests a new immunotherapy drug called cadonilimab for women with cervical cancer that has returned, spread, or is advanced. The goal is to see if it works well, how safe it is, and if it costs less than standard treatments.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This trial tests a new immunotherapy drug, cadonilimab, combined with standard chemotherapy followed by chemoradiation for locally advanced cervical cancer. The goal is to see if this combination works better than current treatments.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.